Abstract

The sweetened deal tabled by Indian Pharmaceutical company Cipla for all of SA's third-largest drug maker Cipla Medpro (Ciplamed) in February, draws a line under a tumultuous four-year period for shareholders. The story is a heady brew of boardroom battles and questionable corporate governance with the whiff of dirty white coat politics lingering in the air.